PharMerica Reports Second Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Sandisk unveils underwhelming outlook despite AI demand surge; shares slip
- Alphabet taps bond market with sweeping 10-part offering to fuel AI ambitions
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Apollo to acquire easyJet for £5.7B in cash deal
- Nielsen to acquire DoubleVerify in merger deal
- Stocks close lower as investors eye Mideast talks, earnings
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
UPDATE: UBS Upgrades PharMerica (PMC) to Buy
August 10, 2015 6:59 AM EDT(Updated - August 10, 2015 9:10 AM EDT)
UBS upgraded PharMerica (NYSE: PMC) from Neutral to Buy with a sum-of-the-parts valuation of $40. Analyst Steven Valiquette is positive on its faster-growing specialty business, reduced litigation overhang, and underappreciated generic pipeline.
"First, we believe the company's faster-growing specialty business which is now could hit $400 mil in revs during '15, a goal PMC mgmt originally set for '16, is now big enough to warrant a 'sum-of-the-parts' valuation vs. simply valuing the... More
Pharmerica (PMC) Tops Q2 EPS by 4c
August 7, 2015 8:05 AM EDTPharmerica (NYSE: PMC) reported Q2 EPS of $0.37, $0.04 better than the analyst estimate of $0.33. Revenue for the quarter came in at $497 million versus the consensus estimate of $491.66 million.
Pharmerica sees FY2015 EPS of $1.55-$1.65, versus the consensus of $1.63. Pharmerica sees FY2015 revenue of $1.95-2.05... More
